Citius Oncology (NASDAQ:CTOR) Trading Up 0.6% – Here’s What Happened

Citius Oncology, Inc. (NASDAQ:CTOR) traded up 0.6% on Wednesday . The company traded as high as $0.6298 and last traded at $0.5732. 116,917 shares were traded during trading, an increase of 110% from the average session volume of 55,782 shares. The stock had previously closed at $0.57.

Analyst Ratings Changes

Separately, Weiss Ratings downgraded Citius Oncology from a “sell (d-)” rating to a “sell (e+)” rating in a research report on Tuesday, July 14th. Two investment analysts have rated the stock with a Buy rating and one has assigned a Sell rating to the company’s stock. According to data from MarketBeat, the company presently has an average rating of “Hold” and a consensus price target of $6.00.

Citius Oncology Stock Down 2.8%

The company has a debt-to-equity ratio of 0.11, a quick ratio of 0.12 and a current ratio of 0.50. The stock’s 50 day moving average price is $0.72 and its 200-day moving average price is $0.87. The company has a market cap of $52.27 million, a PE ratio of -1.20 and a beta of 3.47.

Citius Oncology (NASDAQ:CTOR) last issued its earnings results on Friday, May 15th. The company reported ($0.27) EPS for the quarter, missing analysts’ consensus estimates of ($0.01) by ($0.26). The company had revenue of $1.67 million for the quarter, compared to the consensus estimate of $7.00 million.

Institutional Inflows and Outflows

Large investors have recently modified their holdings of the stock. Citadel Advisors LLC purchased a new stake in Citius Oncology during the 3rd quarter valued at about $36,000. Bank of America Corp DE increased its stake in Citius Oncology by 5,256.9% in the 2nd quarter. Bank of America Corp DE now owns 8,571 shares of the company’s stock worth $37,000 after purchasing an additional 8,411 shares during the period. IFP Advisors Inc increased its stake in Citius Oncology by 49.5% in the 3rd quarter. IFP Advisors Inc now owns 33,215 shares of the company’s stock worth $67,000 after purchasing an additional 11,000 shares during the period. OMERS ADMINISTRATION Corp purchased a new position in Citius Oncology in the 4th quarter worth approximately $104,000. Finally, Geode Capital Management LLC lifted its position in Citius Oncology by 31.6% in the fourth quarter. Geode Capital Management LLC now owns 220,047 shares of the company’s stock valued at $220,000 after purchasing an additional 52,875 shares during the last quarter. Hedge funds and other institutional investors own 70.52% of the company’s stock.

About Citius Oncology

Citius Oncology, Inc is a pharmaceutical company, which engages in developing and commercializing targeted oncology therapies. Its lead product candidate is LYMPHIR, an engineered IL-2 diphtheria toxin fusion protein, for the treatment of patients with persistent or recurrent CTCL, a rare form of non-Hodgkin lymphoma. The company was founded on March 1, 2021 and is headquartered in Cranford, NJ.